Major VC Rounds For AI Companies in Drug Discovery and Biotech in 2022

by Bohdana Sokolova    Contributor 

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   1946    Comments 0
Topics: Biotech Companies   

Despite the economic situation and political climate in 2022, such fields as drug discovery and biotech keep evolving and bringing vital solutions to challenges of the time drawing the attention of venture capitalists (VCs). In this piece let's focus specifically on artificial intelligence (AI)-driven biotech and drug discovery companies which managed to attract investors and raise notable rounds in 2022.

MegaRobo

Mid-June Goldman Sachs took an unusual turn, leading a $300 M round for a Beijing-based startup MegaRobo Technologies known for its muscle power on CRISPR gene editing while promising to combine the power of artificial intelligence and robotics to redefine lab efficiency in creating new drugs with clients. According to CSO at MegaRobo Wang Chengzhi stated that "this financing round will help MegaRobo further strengthen its closed-loop solutions in ‘Automation + Artificial Intelligence + Life Sciences,’ and build the next-generation life sciences infrastructure featuring intelligent automation.”

 

ConcertAI

In March 2022 ConcerAI, the leading enterprise in AI and real-world data (RWD) solutions for life sciences and healthcare, announced the close of its $150 M Series C investment from Sixth Street at a $1.9 B valuation. Over the last 3 years, the company has expanded its customer base and partnerships to more than 45 life sciences companies and contract research organizations (CROs) with SaaS solutions across the product lifecycle: supporting approximately 40 new product launches, improving time on therapy by 10%, and reducing time for study design and projected clinical trial execution times up to 25%.

 

Viz.ai

Continue reading

This content available exclusively for BPT Mebmers

Topics: Biotech Companies   

Share this:              

You may also be interested to read:

 

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *

SHARE